Preview

Медицинский Совет

Расширенный поиск

Ингибитор АПФ фозиноприл в лечении артериальной гипертензии - потенциальные преимущества

https://doi.org/10.21518/2079-701X-2014-7-26-29

Полный текст:

Аннотация

Фозиноприл, имея двойное выведение, может быть использован при почечной недостаточности без коррекции дозировки, что может быть необходимо для пациентов с сахарным диабетом или пожилого возраста даже при нормальном уровне креатинина в плазме крови. Это может служить показанием для применения фозиноприла в качестве препарата выбора у пациентов с почечной недостаточностью и высоким риском заболеваний почек. Фозиноприл может использоваться в качестве монотерапии или в комбинации с гидрохлортиазидом, включая фиксированные комбинации.

Об авторе

А. О. Конради
Федеральный медицинский исследовательский центр им. В.А. Алмазова Минздрава России, Санкт-Петербург
Россия


Список литературы

1. Mac Mahon NB, Cauman S. Effects of ACE inhibitors, calcium antagonists, and other blob pressure lowering drugs: results of prospectively designed overviews of randomized trials. BPLTCT. Lancet, 2004, 345: 1076-1078.

2. Koch M, Thomas B, Tschope E et al. Survival and predictors of death in dialyzed diabetic patients. Diabetologia, 1993, 10: 1515-1516.

3. Walker WG, Cutler J, Neuwirth R et al. Blood pressure and renal function in the Multiple Factor Intervention Trial (MRFIT).J. Hypertens, 1990, 8 (Suppl. 3) VA. 3

4. Kafettz K. Renal impairment in the elderly: a review. J R Soc Med, 1983, 76: 398-401.

5. Hasslacher C, Ritz E, Wahl P et al. Similar risks of nephropathy in patients with type I and type I diabetes mellitus. Nephrol Dialysis Transpl, 1994, 9: 1097-1102.

6. Biesenbach G, Janco O, Zazgornic J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus Nephrol Dialysis Transpl, 1993, 36: 1071-1078.

7. Deedwania PC. Hypertension and diabetes; new therapeutic options. Arch Intern Med, 200, 160: 1985.

8. Freidman JR, Norman DC, Yoshikawa TT et al. Correlation of estimates renal function parameters versus 24-hour creatinine clearance in ambulatory elderly. J Am Geriatr Soc, 1989, 37: 145-149.

9. Rostand SG, Brown G, Kirk KA et al. Renal insufficiency in treated hypertensive patients. NEng J med, 1989, 320: 684-688.

10. Hall A.S. Ace inhibition and target organ protection 1998; Hoechst Marion Roussel. Chapter 7.

11. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of ACE inhibition on diabetic nephropathy. N Eng J Med, 1993, 329: 1456-1462.

12. Viberti GC, Mogenson CE, Groop LC et al. Effects of captopril on progression of clinical proteinuria in patients with insulin-dependent diabetes mellitus. JAMA, 1994, 271: 275-279.

13. Laffel LMB, McGill B, Gans DG et al. The beneficial effect of ACE with captopril on diabetic nephropathy in patients with type 1 diabetes mellitus. Am J med, 1995, 99: 497-504.

14. Ravid M, Lang R, Rachmani R et al. Long-term renoprotective effect of ACE inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med, 1996, 156: 286-289.

15. Trevisan R, Tiergo A., Effect of low-dose ramipril on microalbuminuria in normotensive or mils hypertensive non-insulin diabetic patients. Am J Hypertension, 1995, 8: 876-883.

16. Lebovitz HE, Weigrmann TB, Cnaan A et al. Renal protective effects of enalapril in hypertensive NISSM: role of baseline albumin-uria. Kidney Int, 45: S150-S155.

17. Penegrer TV, Klag MJ, Feldman HI et al, Projections of hypertension-related renal disease in middle-aged residents of the United States. JAMA, 1993, 269: 1272-1277.

18. Ruilope LM, Alcazar JM, Hernandez E et al. Long-term influence of antihypertensive therapy on microalbuminuria in essential hypertension Kydney Int, 1994, 45: 171-173.

19. Martinez M, Moreno A, Aguirre A et al. Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study. J Hypertension, 2001, 19: 319-326.

20. Debusmann ER, Pujadas JO, Lahn W et al. Influence of renal function on the pharmacokinetics of ramipril. Am J Cardiol, 1987, 59: 70D-78D.

21. White CM. Pharmacologic, pharmakinetic and therapeutic differences among ACE inhibitors. Pharmacotherapy, 1998, 18: 588-598.

22. Veller W. Treatment of Senile hypertension. The fosinopril in old patients study. AJH, 1997, 10: 255S-261S.

23. Diercks GF; Janssen WM; van Boven AJ; Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbu-minuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol, 2000, Sep. 15, 86 (6): 635-8.

24. Costanzi S, Fulignati P, Passalacqua S et al. Nephritic syndrome and ACE inhibitors. Nephrol Dial Transplant, 1992, 7: 706-707.

25. Rodicio JL, Praga M, Alcazar JM. Effetcs of ACE inhibitors on the progression of renal failure and proteinuia in humans. J Hypertens, 1989, 7: 543-549.

26. Cansevoort RT, Sluiter WL, Hemmelder MG et al. Antiproteiuretic effect of blood pressure lowering agents: a metaanalysis of clinical trials. Nephrol Dial Transplant, 1995, 10: 1963-1974.

27. Ruiple MR, Aranda AP, Diez SJ et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens, 2001, 10: 1871-1876.


Просмотров: 77


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)